semaglutide dementia Popular diabetes and weight-loss drug may reduce risk of Results from the latest clinical

Retatrutide is often framed as the next step: a triple agonist engaging GLP-1, GIP, and glucagon receptors, extending the incretin-combination concept one receptor further than tirzepatide

The lack of overlap between Glp1r VSM+/+ mice and Glp1r VSM/ proteomic responses strongly support a causal role for the VSMC GLP-1R in renal artery remodeling following GLP-1RA treatment

More recently, dual GIP/GLP-1 RAs, such as tirzepatide, as well as emerging dual and triple incretin-based therapies, have demonstrated substantial efficacy in both glycaemic and weight control

Effect of sodium bicarbonate on prolonged running performance: A randomized, double-blind, cross-over study

Novo Nordisk is in control of GLP-1s such as: Ozempic, Wegovy, Rybelsus and Victoza

Your quote text here How should drug discovery weigh the GLP-1 neurodegeneration story